SubsidieMeestersBioorthogonal Implantable Iontronic Switch to Temporally Control the Local Release of Chemotherapeutics
The project aims to develop an implantable bioSWITCH for on-demand drug delivery to tumors, enhancing treatment efficacy and survival rates in pancreatic cancer.
Projectdetails
Introduction
Our vision for a new type of cancer treatment is based on an implantable therapeutic system capable of programmable on-demand delivery of drugs directly to the tumor. We conceive an implantable iontronic switch (bioSWITCH) to enable a spatiotemporally controlled administration of highly potent chemotherapeutics, without the need for systemic administration of (pro)drugs or drug conjugates.
Technology Overview
This radically new technology will be realized by a combination of next-level tools. As a result, bioSWITCH can generate previously unobtainable discrete as well as continuous drug concentration profiles at the tumor site. This capability allows for the use of highly potent drugs that are otherwise not applicable due to high cytotoxicity.
Goals
The goal is to demonstrate the technology's potential to effectively interfere with tumor progression using a xenograft pancreas cancer mouse model. Efficiently shrinking tumors in size allows for surgical resection of previously non-operable tumors and dramatically increases survival rates.
Consortium
Our consortium of world-leading academics and pioneering SMEs will ensure the translation of this disruptive technology into the market to maximize the socioeconomic impact.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 4.420.511 |
| Totale projectbegroting | € 4.420.511 |
Tijdlijn
| Startdatum | 1-3-2023 |
| Einddatum | 28-2-2026 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- LINKOPINGS UNIVERSITETpenvoerder
- TAGWORKS PHARMACEUTICALS BV
- TECHNISCHE UNIVERSITAET WIEN
- SUPRAPOLIX BV
- MEDIZINISCHE UNIVERSITAT GRAZ
- OBOE IPR AB
- HUN-REN TERMESZETTUDOMANYI KUTATOKOZPONT
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
On-Demand Bioresorbable OptoElectronic System for In-Vivo and In-Situ Monitoring of Chemotherapeutic DrugsDevelop a bioresorbable chemical sensing system for real-time monitoring of doxorubicin in-vivo, enhancing personalized cancer treatment while eliminating the need for device retrieval surgery. | EIC Pathfinder | € 2.606.250 | 2022 | Details |
Functional chemical reprogramming of cancer cells to induce antitumor immunityThe RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments. | EIC Pathfinder | € 2.966.695 | 2024 | Details |
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy. | EIC Pathfinder | € 5.972.875 | 2024 | Details |
In-situ & operando organiC electrochemical transistors monitored by non-destructive spectroscopies for Organic cmos-like NeuromorphIc CircuitsICONIC aims to advance implantable AI organic electronic devices for chronic disease management by investigating PMIECs, leading to smart drug-delivery systems with enhanced accuracy and safety. | EIC Pathfinder | € 2.664.940 | 2024 | Details |
On-chip tomographic microscopy: a paraDIgm Shift for RevolUtionizing lab-on-a-chiP bioimaging technologyDISRUPT aims to revolutionize biomedical imaging with a novel lab-on-chip technology for cost-effective, high-resolution cancer detection and diagnostics using integrated tomographic microscopy and AI. | EIC Pathfinder | € 3.018.312 | 2022 | Details |
On-Demand Bioresorbable OptoElectronic System for In-Vivo and In-Situ Monitoring of Chemotherapeutic Drugs
Develop a bioresorbable chemical sensing system for real-time monitoring of doxorubicin in-vivo, enhancing personalized cancer treatment while eliminating the need for device retrieval surgery.
Functional chemical reprogramming of cancer cells to induce antitumor immunity
The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.
NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.
In-situ & operando organiC electrochemical transistors monitored by non-destructive spectroscopies for Organic cmos-like NeuromorphIc Circuits
ICONIC aims to advance implantable AI organic electronic devices for chronic disease management by investigating PMIECs, leading to smart drug-delivery systems with enhanced accuracy and safety.
On-chip tomographic microscopy: a paraDIgm Shift for RevolUtionizing lab-on-a-chiP bioimaging technology
DISRUPT aims to revolutionize biomedical imaging with a novel lab-on-chip technology for cost-effective, high-resolution cancer detection and diagnostics using integrated tomographic microscopy and AI.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Bioorthogonal Iontronic Chemistry: Spatiotemporal Drug Release with Electronic PrecisionDevelop a programmable drug delivery system using Biontronic Chemistry for precise spatiotemporal release, enhancing treatment efficacy while minimizing side effects in various therapies. | ERC Starting... | € 1.496.795 | 2024 | Details |
Preclinical validation and market analysis of a microMESH implant for brain cancer eradicationThe project aims to develop and validate a novel drug delivery implant, microMESH, for targeted chemo-immunotherapy in glioblastoma, enhancing treatment efficacy and patient outcomes. | ERC Proof of... | € 150.000 | 2022 | Details |
Nano-assisted digitalizing of cancer phenotyping for immunotherapyThe ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes. | ERC Consolid... | € 1.993.875 | 2023 | Details |
Unlocking a T cell-mediated Immune response in therapy-challenged TumorsUnlockIT aims to develop mechanism-based combination therapies for cancer by understanding tumor-immune interactions and enhancing T cell responses in therapy-challenged tumors. | ERC Consolid... | € 2.000.000 | 2024 | Details |
Bioorthogonal Cascade-Targeting: Directing Drugs into Cells with Molecular PrecisionDevelop bioorthogonal cascade-targeting methods for precise, safe, and efficient intracellular delivery of therapeutics, enhancing drug targeting and minimizing collateral damage. | ERC Starting... | € 1.479.321 | 2023 | Details |
Bioorthogonal Iontronic Chemistry: Spatiotemporal Drug Release with Electronic Precision
Develop a programmable drug delivery system using Biontronic Chemistry for precise spatiotemporal release, enhancing treatment efficacy while minimizing side effects in various therapies.
Preclinical validation and market analysis of a microMESH implant for brain cancer eradication
The project aims to develop and validate a novel drug delivery implant, microMESH, for targeted chemo-immunotherapy in glioblastoma, enhancing treatment efficacy and patient outcomes.
Nano-assisted digitalizing of cancer phenotyping for immunotherapy
The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.
Unlocking a T cell-mediated Immune response in therapy-challenged Tumors
UnlockIT aims to develop mechanism-based combination therapies for cancer by understanding tumor-immune interactions and enhancing T cell responses in therapy-challenged tumors.
Bioorthogonal Cascade-Targeting: Directing Drugs into Cells with Molecular Precision
Develop bioorthogonal cascade-targeting methods for precise, safe, and efficient intracellular delivery of therapeutics, enhancing drug targeting and minimizing collateral damage.